Levene, Dombeck, Kasischke, Molloy, and Webb (Cornell) showed that a 350-Β΅m-diameter composite GRIN lens (two 0.6-NA end pieces, pitch 0.22, glued to a 0.1-NA pitch-1 relay, ~16 mm total) inserted through a 5-mm craniotomy into anesthetized Thy1-YFP line H mice delivered multiphoton imaging far beyond the conventional ~500 Β΅m limit .
Measured performance: lateral PSF FWHM 825 nm (vs. 481 nm diffraction limit), axial PSF ~15 Β΅m (attributed to spherical aberration), 59% objective coupling efficiency, 66% lens transmission (~40% overall excitation efficiency), 58-Β΅m field of view, and ~2,700 fsΒ² pulse dispersion requiring no compensation .
Tail-vein fluorescein-dextran or quantum-dot labeling enabled microangiography: a ~5-Β΅m capillary and a ~15-Β΅m vessel were imaged >2 mm deep, and line-scan flow analysis gave ~0.6 mm/s β consistent with prior rat cortex values . The authors candidly addressed trauma: inevitable vessel cleavage along the 600-Β΅m penetration track, limited (~10 Β΅m) tissue compression, and likely chronic gliosis β though they argued gliosis from prior electrode studies stays within the ~60-Β΅m working distance.
Strengths: quantified PSF and efficiency metrics, honest treatment of trauma, and a paradigm-setting demonstration. Weaknesses: acute imaging only in anesthetized animals (no chronic validation despite gliosis speculation); no histological confirmation of tissue damage; no motion-artifact quantification; field of view only 58 Β΅m; no comparison images from a surface microscope as internal control. The claim that chronic implantation "may" work is conjecture, not data. These gaps were later filled by the field β e.g., large-FOV three-photon work reaching >1.1 mm , and computational adaptive-optics two-photon approaches .
A landmark methods paper (2003 submission, ~900 citations, two known recent citing works ). Confidence: high for the reported optical metrics and imaging depths; moderate for trauma claims lacking histology.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.